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Abstract
Background: The aim of this study was to determine whether clinical outcome of patients with
methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia was correlated with vancomycin
susceptibility of the corresponding strains.
Methods: A retrospective study on MRSA bacteraemia was performed at a teaching hospital
between January 1998 and October 2005 by linking vancomycin susceptibility profiles of patients'
isolates with hospitalization data.
Results: A total of 20 out of 209 MRSA bacteraemia patients were treated with vancomycin for
at least 5 days with adequate trough levels, and fulfilled the study's inclusion and exclusion criteria.
Twenty-two  S. aureus isolates from these patients' blood cultures were identified as MRSA,
including two hetero-VISA from separate patients and two VISA with vancomycin MIC of 4 mg/L
from one patient. Between patients who showed 'good' vancomycin response and patients who did
not, there was a significant difference (p < 0.01) in their corresponding MRSAs' vancomycin
susceptibility expressed by 'area under curve' (AUC) of population analysis. Significant correlations
were found between AUC and initial vancomycin therapeutic response parameters of 'days till
afebrile' (r = 0.828, p < 0.01) and 'days till CRP  30% of maximum' (r = 0.627, p < 0.01)
Conclusion: Our study results caution healthcare personnel that early consideration should be
given to cases with a poor vancomycin treatment response that could signify the involvement of
MRSA with reduced susceptibility to vancomycin.
1. Introduction
Vancomycin has been the agent of choice for methicillin-
resistant Staphylococcus aureus (MRSA) infections as it pro-
vided efficacious and promising therapy [1]. Nevertheless,
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with the emergence of S. aureus strains having intermedi-
ate resistance towards vancomycin (vancomycin-interme-
diate  S. aureus [VISA]), treatment options for patients
infected with these strains have become limited [2]. Het-
ero-VISA strains are also being reported more frequently
worldwide [3]. These strains are interpreted as 'suscepti-
ble' to vancomycin using conventional MIC determina-
tion tests, but contain a sub-population of cells which can
grow in the presence of > 2 mg/L vancomycin [3]. Clinical
significance of hetero-VISA is still controversial [1,2].
Therefore, it is important to elucidate whether vancomy-
cin susceptibility of clinical MRSA strains is correlated
with the corresponding patients' clinical outcome. We
report here the results of a retrospective study that was car-
ried out to investigate the existence of the above correla-
tion.
2. Methods
2.1 Setting
A retrospective study on MRSA bloodstream infections at
Juntendo University Hospital, Tokyo, Japan, between Jan-
uary 1998 and October 2005 was carried out. The inclu-
sion criterion of the study was defined as febrile patients
(body temperature > 37°C) with at least one MRSA posi-
tive blood culture, and had been treated with a mono-
therapy of vancomycin for at least 5 days. In addition,
serum vancomycin trough levels should have been main-
tained above 10 mg/L [4]. Patients who had catheter-asso-
ciated MRSA bloodstream infections (CABSI) were also
included in the study; however, they were excluded if their
CABSI is a catheter related bloodstream infection
(CRBSI), since CRBSIs are usually self-limiting, and recov-
ery could be achieved with the removal of contaminated
catheters without antibiotic treatment. The diagnosis for
CABSI and CRBSI was done using the Center for Disease
Control (CDC) definition of catheter-related infections
for National Nosocomial Infection Surveillance (NNIS)
[5].
2.2 Medical record review and definitions
Medical records of patients eligible for this study were
reviewed to retrieve information such as demographic fac-
tors (age and gender) and their medical history. The
patients' underlying conditions were then evaluated
according to the American Society of Anesthesiologists
(ASA) scoring system [6]. Besides this, each case's initial
therapeutic response parameters towards vancomycin
were recorded. The parameters used in this study were
'days till afebrile', 'days till CRP value  30% of maxi-
mum' and 'days till WBC < 10,000'. A parameter of 'days
till afebrile' was defined as the number of days required
for the patient's defervescence (body temperature becom-
ing less than 37°C) after commencement of vancomycin
therapy, while 'days till CRP  30% of maximum' refers
to the number of days required for the reduction of
patient's CRP level to less than 30% of the maximum
value during active infection, after vancomycin was
administered. The number of days required for patients'
white blood cell count to return to the normal range of
~10,000 cells/mm3 after initiation of vancomycin therapy
was defined as 'days till WBC < 10,000'. If the patient had
died during treatment, the above parameters would then
refer to the number of days from the day of vancomycin
commencement till death for each parameter. The dura-
tion of MRSA blood culture positivity during vancomycin
therapy was also noted for each patient, as well as the
patient's survival at one month after the onset of MRSA
bloodstream infection. Patient's response to vancomycin
therapy was defined as either 'good' or 'poor' [7]. 'Good'
represents cases where patients were cured, with elimina-
tion of clinical symptoms and laboratory evidence of
infection; patients who were apparently cured but died
due to other causes were also included in this category.
'Poor' is defined for cases with persistence or worsening of
symptoms and also cases where the patient died due to
the bloodstream infection itself.
2.3 Laboratory investigations
2.3.1 Bacterial strains
All MRSA blood stream isolates used in this study were
recovered from hospitalized patients in Juntendo Univer-
sity Hospital between January 1998 and October 2005.
Only the initial isolate for each patient was used for labo-
ratory investigations. Reference hetero-VISA strain Mu3
and VISA strain Mu50 were isolated in January and Sep-
tember 1996, respectively, at the same hospital [3,8]. Van-
comycin-susceptible MRSA strain N315 was isolated in
1982 from the pharyngeal smear of a Japanese patient [3].
Identification of S. aureus was confirmed by Gram's stain,
catalase test and slide latex agglutination test (STAPHYLO
LA "SEIKEN", Denka Seiken Co., Ltd., Japan) [9]. Strains
were stocked from time of isolation in Mueller-Hinton
broth with 40% glycerol at -70°C.
2.3.2 Antibiotic susceptibility testing
Vancomycin minimum inhibitory concentrations (MIC)
for all isolates were determined using the agar dilution
method in accordance with the Clinical and Laboratory
Standards Institute (CLSI) recommendations [10]. Analy-
sis of vancomycin-resistant subpopulation (population
analysis) for all strains was carried out as described previ-
ously [3]. Log graphs of viable count versus vancomycin
concentrations were plotted and area under curve (AUC)
was then calculated [11].
2.4 Statistical analysis
Independent t-tests were used to compare the means of
AUC between patients showing 'good' or 'poor' vancomy-
cin response. Pearson's correlation tests were use to deter-
mine the correlation between MRSA vancomycinAnnals of Clinical Microbiology and Antimicrobials 2007, 6:13 http://www.ann-clinmicrob.com/content/6/1/13
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susceptibilities and corresponding patients' initial thera-
peutic response parameters of 'days till afebrile' and 'days
till CRP  30% of maximum'. All statistical analyses were
performed using SPSS 11.5J for Windows (LEAD Technol-
ogies, INC.).
3. Results and discussion
This study was performed to investigate the relationship
between vancomycin susceptibility of MRSA and the cor-
responding patients' clinical outcome. The true clinical
relevance of hetero-resistance or intermediate resistance
to vancomycin in S. aureus may be obscured because of
uncertainty of the patients' clinical conditions. Many pub-
lished case reports did not provide sufficient details to
assess the role of the infection itself, nor of the antibiotic
treatment in the clinical course of individual patients. Our
study was designed to include only clinically significant
cases of MRSA bloodstream infection that received vanco-
mycin monotherapy, and to determine whether vancomy-
cin susceptibility of the causative MRSA correlated with
the clinical efficacy of vancomycin in the treatment of
these infections. To achieve this, a strict inclusion and
exclusion criteria for selection of clinical cases was
employed throughout the study (see methods). Based on
the study's inclusion and exclusion criteria, a total of 20
patients, with a mean age of 54.5 years comprising 12
men and 8 women, were eligible for this study. The
patients' clinical history is summarized in Table 1. While
these patients had various underlying diseases, they could
be mainly categorized into cancer, circulatory system dis-
order or diabetic patients. Patients were hospitalized for a
mean duration of 135.9 ± 109.03 days, while mean dura-
tion of vancomycin treatment was 13.8 ± 5.58 days,
respectively. Four patients were MRSA nasal carriers when
they were admitted. Eighteen patients had insertion of
Table 1: Clinical summary of patients eligible for this study
Pt no. Sex Age Underlying disease ASAa Hospitalization 
days
VCM 
Treatment daysb
Shock Infection 
source
MRSA 
carriere
1 M 58 Extraheptic bile duct carcinoma, 
post operation liver failure
IV 86 9 yes SSIc no
2 F 28 Pneumonia, alchoholic hepatitis III 92 5 yes (DIC) CVC no
3 F 25 Multiple sclerosis, steroids therapy III 67 20 no transfusion no
4 M 66 Liver cirrhosis, renal dialysis, brain 
stroke
IV 129 19 yes (DIC) unknown no
5 M 70 Renal dialysis, brain stroke, surgery in 
admission
IV 85 12 yes SSI no
6 F 91 Diabetes, chronic heart failure IV 252 16 no CVCd yes
7 M 22 Germ cell tumour, chemotherapy III 301 9 no CVC yes
8 M 63 Diabetes, brain stroke, aspiration IV 260 11 yes unknown no
9 F 57 Diabetes, SLE, surgery in admission IV 137 23 yes pressure sore yes
10 M 38 Lung cancer, chemotherapy, metastasis IV 105 19 no pressure sore no
11 F 73 Brain stroke, aspiration, surgery in 
admission
IV 43 15 no CVC yes
12 F 3 B cell lymphoproliferative disorder, 
steroids
III 50 8 no CVC yes
13 M 77 Diabetes, chronic renal failure, 
aspiration
IV 281 10 no CVC no
14 M 59 Renal cancer, metastasis to bone, lung IV 111 7 no CVC no
15 M 79 Lung cancer, chemotherapy III 430 17 no cellulitis no
16 M 57 Non-Hodgkin's lymphoma, 
chemotherapy
IV 21 14 no unknown no
17 F 67 Liver cancer, liver cirrhosis, 
hypertension
III 69 9 no port no
18 F 22 Pulmonary embolism, bone tumour 
transplantation
III 86 19 no transplantation no
19 M 72 Encephalopathy, apical OMI, aspiration 
pneumonia
IV 59 10 no CVC no
20 M 62 Heart failure, acute myocardial infarct IV 54 24 yes CVC no
a) ASA (American Association of Anaesthetists) scoring to assess patients' underlying conditions: I, a completely healthy patient; II, a patient with 
mild systemic disease; III, a patient with severe systemic disease that is not incapacitating; IV, a patient with incapacitating disease that is a constant 
threat to life; V, a moribundpatient who is not expected to live 24 hours with or without surgery.
b) Duration of vancomycin treatment
c) SSI, surgical site infection
d) CVC, central venous catheter
e) MRSA nasal carrier during hospital admissionAnnals of Clinical Microbiology and Antimicrobials 2007, 6:13 http://www.ann-clinmicrob.com/content/6/1/13
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catheters and this was suspected to be the cause of CABSI
in 10 cases.
To support our study design, only blood cultures were
used in the laboratory investigation, strains obtained from
tips or catheters were excluded. Initial isolates of all
patients had vancomycin MIC levels within the suscepti-
ble range (1–2 mg/L); while two subsequent MRSA strains
from patient no.15 isolated during vancomycin therapy
had both vancomycin MICs of 4 mg/L each, and were
judged as VISA according to CLSI criteria, Jan. 2006 [10].
Patient no. 15 was admitted on 28th October 2004 for
small cell lung carcinoma. He developed MRSA cellulites,
which was treated with vancomycin from 28th Novem-
ber. MRSA was then isolated from his blood on 3rd
December. Vancomycin treatment was given until 14th
December, but the patient's condition worsened. Subse-
quently, two VISA strains were isolated from his blood on
21st and 25th December, and these three bloodstream
isolates showed identical band patterns in pulsed field gel
electrophoresis (Data not shown). Finally, this patient
recovered from sepsis by a combination therapy of vanco-
mycin with arbekacin. This patient's clinical course under-
scores the clinical impact of hetero-VISA, generally
recognized as "vancomycin-susceptible" MRSA based on
MIC data alone, that cause slow and poor vancomycin
therapeutic response. It is considered that hetero-VISA ini-
tiates apparently regular MRSA infection, but soon gener-
ates VISA within the patient's body during vancomycin
therapy, eventually causing therapeutic failure.
Vancomycin treatment failures are not uncommon with
MRSA infections despite the organism being fully suscep-
tible (vancomycin MIC  2 mg/L) according to standard
clinical laboratory testing methods [12]. Even though the
clinical course of patients in this study were not entirely
similar, all their initial MRSA strains had vancomycin
MICs of 1–2 mg/L, which were in the 'susceptible' range.
This implies the possibility, though small, that different
vancomycin susceptibility levels within the 'susceptible'
range may result in dissimilar clinical outcome. To dis-
criminate in more detail the vancomycin susceptibility of
these strains, we employed population analysis (PA)
methods, which can provide vancomycin susceptible pro-
file for individual cell [3]. The area under curve (AUC) for
each strain's population analysis profile was calculated
and presented in Table 2, along with the clinical course of
each strain's corresponding patient. The AUC represents
the strains' resistance level to vancomycin [11]. We found
that mean AUC of strains from patients who showed
'good' vancomycin response was 10.81 ± 1.66, and those
from patients who showed 'poor' vancomycin response
was 16.09 ± 5.09, showing significant difference in the
vancomycin susceptibility between these two patient
groups' MRSA (p < 0.01). Two strains, 02-6 and 03-10
from patient no.4 and patient no.9, respectively, had high
AUC values and were judged as hetero-VISA from their PA
profiles [3,11]. These patients had 'poor' vancomycin
treatment response and died as a result of the blood-
stream infection (Table 2). Figure 1 shows PA profiles of
representative strains with control strains Mu3, Mu50 and
N315. This finding further emphasizes the impact of
reduced MRSA vancomycin susceptibilities towards
patients' clinical course in bloodstream infections.
To further understand the effect of MRSA vancomycin sus-
ceptibility on the corresponding patient's clinical course,
we evaluated the initial therapeutic response of each
patient's infection towards vancomycin. For this evalua-
tion, 3 parameters were used, namely 'days till afebrile',
'days till CRP  30% of maximum' and 'days till WBC <
10,000' (see methods). While the parameters of afebrile
and white blood cell count are more established, the
parameter of 'days till CRP  30% of maximum' is com-
monly used in Japan to assess the efficacy of antimicrobi-
als towards infection [13]. Correlation tests were
performed to investigate if there was any correlation
between vancomycin susceptibility of the initial MRSA
strains (AUC) of every patient with each of the above
parameters. Results showed a significant positive linear
correlation between AUC and the corresponding patients'
initial therapeutic response parameters of 'days till afe-
brile' (r = 0.828, P < 0.01), and 'days till CRP  30% of
maximum' (r = 0.627, P < 0.01). The less susceptible the
MRSA strain was to vancomycin, the longer it took for the
patient to become afebrile and for his/her CRP value to
return to normal (Table 2). This supports Charles et al.'s
results where patients infected by hetero-VISA took a
longer time to defervescence [14], and also indicates that
various levels of vancomycin susceptibility in MRSA
strains play a critical role as a determinant in patients'
clinical outcome in bloodstream infections. Therefore, it
is desirable to identify such infected cases and to initiate
optimal treatment for these infections early in the clinical
course; good communication between the clinician and
clinical laboratory is essential for this purpose. In addi-
tion, improvement in clinical outcome may be achieved if
early consideration is given to patients who show a slow
initial therapeutic response that could signify the involve-
ment of MRSA strains with reduced susceptibility to van-
comycin. Nevertheless, the initial therapeutic response
parameter of 'days till WBC <10,000' could not be used as
a determinant of patient's clinical course in our study.
This is due to the reason that most of the patients enrolled
in our study were either leukopenic or had leukocytosis
even before the initiation of vancomycin, and therefore
no conclusive data could be derived from this parameter.
In contrast to another report [14], the number of MRSA
positive blood cultures could not be used as a parameterAnnals of Clinical Microbiology and Antimicrobials 2007, 6:13 http://www.ann-clinmicrob.com/content/6/1/13
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to assess the impact of MRSA vancomycin susceptibility
on patients' clinical outcome in our study. Blood culture
is not a routine test in Juntendo University Hospital,
therefore there were no continuity of blood culture results
for certain patients. In addition, we observed that MRSA
blood culture positivity was not definitive of a patient's
infection status. This could be seen in the case of patient
no.15, as even though he had a MRSA negative blood cul-
ture after 4 days of vancomycin therapy, this patient's
bloodstream infection worsened and VISA was isolated
from his blood 3 weeks later, as opposed to the case of
patient no. 13 where this patient had a relatively fast
recovery from infection even though it took 18 days for
his blood culture to be MRSA negative. Patient survival
rate at one month was also not conclusive to predict the
relationship between reduced MRSA vancomycin suscep-
tibility and patient outcome in our study. This is because
even though some mortalities in our study were due to
MRSA bloodstream infection, there were also patients
Table 2: Microbiological profile of MRSA strains and clinical outcome of corresponding patients
Patient MRSA strains VCM MIC 
(mg/L)a
AUCb 
(days)
DTAc 
(days)
DTCRPd 
(days)
DTWBCe 
(days)
DBCPf 
(days)
Survival at 
one month
VTRg
1 98-7 2 18.94 10 10 <10,000 n.a. dead Poor
2 99-7 2 12.3 10 10 > 10,000 10 dead Poor
3 01-3 1 10.95 6 8 <10,000 n.a. alive Good
4 02-6 2 22.01 19 19 > 10,000 n.a. dead Poor
5 03-1 1 9.12 5 6 1 8 dead Good
6 03-3 1 10.57 4 8 9 15 alive Good
7 03-5 1 8.54 3 6 <10,000 n.a. alive Good
8 03-9 1 12.56 12 2 <10,000 2 dead Good
9 03-10 2 23.11 25 12 7 13 dead Poor
10 03-13 1 7.62 2 4 > 10,000 n.a. dead Good
11 03-16 1 11.56 15 12 8 n.a. transferred Poor
12 03-29 1 11.14 4 3 <10,000 4 alive Good
13 04-6 1 10.88 5 9 6 16 dead Good
14 04-13 1 9.84 4 7 <10,000 18 dead Good
15 04-15 1 11.92 12 12 < 10,000 4 alive Poor
16 04-17 1 12.81 14 15 <10,000 10 alive Poor
17 05-1 1 11.39 10 8 <10,000 n.a. discharged Good
18 05-4 1 12.19 8 8 <10,000 11 alive Good
19 05-10 1 13.08 6 9 no change n.a. alive Good
20 05-12 1 12.59 10 6 6 9 dead Good
a) Minimum inhibitory concentrations (MIC) for vancomycin was determined using the agar dilution method in accordance with the Clinical and 
Laboratory Standards Institute (CLSI) recommendations (9).
b) AUC (area under curve), measurements of polulation analysis profiles for vancomycin. Log of viable colonies were ploted against vancomycin 
concentration. AUC represents area covered by curve and graph axis.
c) DTA (days till afebrile), represents number of days required for the patient's defervesence (body temperature less than 37°C) after 
commencement of vancomycin therapy.
d) DTCRP (days till CRP  30% of maximum), refers to the number of days required for the reduction of patient's CRP level to less than 30% of 
the maximum value during active infection, after vancomycin was administered.
e) DTWBC (days till white blood cell < 10,000), refers to the number of days needed for patients' white blood cell level to return to the normal 
range of ~10,000 cell/mm3.
f) DBCP refers to duration of MRSA blood culture positivity during vancomycin therapy.
g) VTR (vancomycin treatment response), was defined as either 'good' or 'poor'. 'Good' repersents complete cure or elimination of clinical 
symptoms and elimination of laboratory evidence of infection, while 'poor' stands for persistence or worsening of symptoms or death due to MRSA 
bloodstream infection.
Population analysis profiles of representative strains and con- trol strains Figure 1
Population analysis profiles of representative strains and con-
trol strains. Symbols: open circles, strain Mu50; open 
squares, strain Mu3; open triangles, strain N315; closed cir-
cles, hetero-VISA 02-6; closed squares, hetero-VISA 03-10; 
closed triangles, VISA 04-18; closed diamonds, VISA 04-19.
0
1
2
3
4
5
6
7
8
012345678
N
u
m
b
e
r
 
o
f
 
c
o
l
o
n
y
 
f
o
r
m
i
n
g
 
u
n
i
t
 
(
l
o
g
1
0
)
Vancomycin concentration (mg/L)Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Annals of Clinical Microbiology and Antimicrobials 2007, 6:13 http://www.ann-clinmicrob.com/content/6/1/13
Page 6 of 6
(page number not for citation purposes)
who died due to their underlying diseases such as cancer
and heart failure.
Although our results were statistically significant, limita-
tion of this study includes its small sample size and retro-
spective design. Patient sampling was difficult due to the
strict inclusion and exclusion criteria employed in our
study; for example, patients were frequently given vanco-
mycin together with antibiotics of different classes. There
were patients who died after one or two days vancomycin
therapy due to the severity of their infection, patients who
were not given vancomycin due to their underlying dis-
eases, and there were also cases where vancomycin trough
levels were not sufficient to meet the criteria. We did not
include these cases into our current investigation as it
might introduce bias into the study. An extended, progres-
sive study would be needed to fully establish the correla-
tion between patient clinical outcome and vancomycin
susceptibility of the causative MRSA.
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